<p>Shikiar Asset Management Inc. 在最近向證券交易委員會的披露中表示，在第三季度減少了對 Incyte Corporation (NASDAQ:INCY - 免費報告) 的持股，降幅為 15.8%。該機構投資者在本季度出售了 18,045 股後，持有 95,950 股這家生物製藥公司的股票。Incyte 在 Shikiar Asset Management Inc. 的投資組合中佔約 2.0%，是其第 15 大持倉。Shikiar Asset Management Inc. 在 Incyte 的持股在最近一個季度末價值為 8,138,000 美元。</p>
<ul>
<li>Incyte 能否實現 447% 的每股收益預測和管道熱度？</li>
</ul>
<p>其他機構投資者也買賣了該公司的股票。捷克國家銀行在第二季度將其在 Incyte 的持股增加了 6.4%。捷克國家銀行目前持有 39,271 股這家生物製藥公司的股票，價值 2,674,000 美元，此前在上個季度增持了 2,378 股。denkapparat Operations GmbH 在第二季度將其在 Incyte 的持倉增加了 46.1%。denkapparat Operations GmbH 目前持有 11,292 股這家生物製藥公司的股票，價值 769,000 美元，此前增持了 3,564 股。Hussman Strategic Advisors Inc. 在第二季度將其在 Incyte 的持股增加了 20.0%。Hussman Strategic Advisors Inc. 目前持有 63,000 股這家生物製藥公司的股票，價值 4,290,000 美元，此前增持了 10,500 股。Fisher Asset Management LLC 在第二季度將其在 Incyte 的持股增加了 74.6%。Fisher Asset Management LLC 目前持有 29,922 股這家生物製藥公司的股票，價值 2,038,000 美元，此前增持了 12,785 股。最後，Strid Group LLC 在第二季度購買了價值 999,000 美元的 Incyte 新股。機構投資者目前持有該公司 96.97% 的股票。</p>
<h2>內部人士下注</h2>
<p>在其他 Incyte 的新聞中，執行副總裁 Steven H. Stein 於 12 月 2 日星期二出售了 20,105 股該股票。股票以平均價格 102.51 美元出售，總交易額為 2,060,963.55 美元。出售完成後，該執行副總裁直接持有 63,129 股公司股票，價值約 6,471,353.79 美元。這代表其持股減少了 24.15%。該交易在向 SEC 的文件中披露，可以通過此鏈接訪問。此外，內部人士 Thomas Tray 於 12 月 19 日星期五出售了 2,774 股公司的股票。股票以平均價格 100.00 美元出售，總交易額為 277,400.00 美元。出售完成後，該內部人士在公司中持有 22,973 股，價值 2,297,300 美元。這代表其持股減少了 10.77%。該銷售的披露在 SEC 文件中可用。內部人士在過去三個月內共出售了價值 8,708,893 美元的 88,318 股公司股票。當前 17.80% 的股票由內部人士持有。</p>
<h2>Incyte 關鍵新聞</h2>
<ul>
<li>2024 年盈利增長的 5 大醫療保健股票</li>
</ul>
<p>以下是本週影響 Incyte 的關鍵新聞：</p>
<ul>
<li>積極情緒：日本批准擴大商業足跡——日本衞生當局批准了 Zynyz® (retifanlimab) 用於一線晚期肛門癌，並批准了 Minjuvi® (tafasitamab) 與利妥昔單抗和來那度胺聯合用於復發/難治性濾泡淋巴瘤，為一個重要市場開闢了增量收入機會。閲讀更多。閲讀更多。</li>
<li>積極情緒：分析師動能和目標價格上調——幾家公司最近提高了 INCY 的目標或進行了升級（例如 Guggenheim 和 Barclays），這支持了中期收入/盈利的積極敍述。閲讀更多。</li>
<li>中性情緒：價格走勢顯示投資者興趣但仍存謹慎——Zacks 的一篇文章指出，前一交易日的交易量超過平均水平，股價上漲約 5.5%，但警告稱最近的盈利預測修訂可能限制短期上漲，暗示在沒有進一步數據的情況下，動能可能不持久。閲讀更多。</li>
<li>消極情緒：內部人士出售可能增加賣壓——董事/高管 Thomas Tray 披露在 12 月 18 日至 19 日期間共出售 3,374 股（平均價格約為 98–100 美元），並報告了其他內部人士交易；集中內部人士出售可能會發出短期壓力信號或促使投資者保持謹慎。</li>
</ul>
<h2>Incyte 股票下跌 1.9%</h2>
<p>NASDAQ INCY 的股票在星期二開盤價為 100.71 美元。該公司的流動比率為 3.20，速動比率為 3.13，債務與股本比率為 0.01。該股票的市值為 197.7 億美元，市盈率為 16.87，市盈增長比率為 0.70，貝塔值為 0.81。該股票的 50 日簡單移動平均線為 98.53 美元，200 日簡單移動平均線為 85.09 美元。Incyte Corporation 的 12 個月低點為 53.56 美元，12 個月高點為 109.28 美元。</p>
<ul>
<li>Argenx 的 28% 激增及有前景的產品提升投資者信心</li>
</ul>
<p>Incyte (NASDAQ:INCY - 獲取免費報告) 最近於 10 月 28 日星期二發佈了季度財報。這家生物製藥公司報告本季度每股收益為 2.26 美元，超出市場共識預期的 1.65 美元，超出幅度為 0.61 美元。Incyte 的股本回報率為 26.56%，淨利潤率為 24.69%。該公司本季度的收入為 13.7 億美元，而分析師預期為 12.6 億美元。在去年同期，該公司每股收益為 1.07 美元。該公司的季度收入較去年同期增長了 20.0%。整體而言，分析師預計 Incyte Corporation 本財年將發佈 4.86 美元的每股收益。</p>
<h2>分析師設定新目標價格</h2>
<p>幾位研究分析師最近對 INCY 股票發表了評論。Stifel Nicolaus 將 Incyte 的股票目標價從 110.00 美元上調至 115.00 美元，並在 9 月 22 日的研究報告中給予該股票 “買入” 評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Incyte 股票的 “持有（c+）” 評級。摩根士丹利將 Incyte 的目標價從 86.00 美元上調至 92.00 美元，並在 12 月 8 日的報告中給予該公司 “等權重” 評級。Piper Sandler 將 Incyte 的目標價從 82.00 美元上調至 102.00 美元，並在 11 月 4 日的報告中給予該股票 “超配” 評級。最後，巴克萊將 Incyte 的目標價從 101.00 美元上調至 115.00 美元，並在 11 月 24 日的研究報告中給予該股票 “超配” 評級。八位投資分析師對該股票給予了 “買入” 評級，十一位給予了 “持有” 評級，一位則給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “持有”，共識目標價為 99.07 美元。</p>
<p><strong>閲讀我們關於 Incyte 的最新股票分析</strong></p>
<h2>關於 Incyte</h2>
<p>（免費報告）</p>
<p>Incyte Corporation 是一家總部位於特拉華州威爾明頓的生物製藥公司，專注於腫瘤學和炎症領域新療法的發現、開發和商業化。自 2002 年成立以來，Incyte 已從一家小型研究機構發展為一家全球企業，推進一系列內部開發和合作的資產。公司的研發工作集中在小分子藥物和生物製劑上，這些藥物和生物製劑能夠調節與癌症、自身免疫疾病和罕見疾病相關的關鍵信號通路。</p>
<p>公司的旗艦產品是 Jakafi®（ruxolitinib），這是一種被批准用於治療骨髓纖維化和真性紅細胞增多症的 Janus 激酶（JAK）抑制劑。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “3 美元人工智能奇蹟股票” 即將爆發</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>資本利得税是否可以扣除任何費用？</li>
<li>最後的黃金牛市</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Incyte 嗎？</h2>
<p>在你考慮 Incyte 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Incyte 並不在名單上。</p>
<p>雖然 Incyte 目前在分析師中獲得了 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

因塞特醫療

<p>Shikiar Asset Management Inc. 在第三季度減少了對因塞特醫療的持股比例，下降了 15.8%，出售了 18,045 股。內部交易包括執行副總裁 Steven H. Stein 出售了 20,105 股，內部人士 Thomas Tray 出售了 2,774 股。因塞特醫療的股票開盤價為 100.71 美元，市值為 197.7 億美元。近期分析師的升級和日本對關鍵藥物的批准可能會影響未來的收益</p>

<p>Shikiar Asset Management Inc. decreased its holdings in shares of Incyte Corporation (NASDAQ:INCY - Free Report) by 15.8% during the third quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor owned 95,950 shares of the biopharmaceutical company's stock after selling 18,045 shares during the quarter. Incyte comprises about 2.0% of Shikiar Asset Management Inc.'s investment portfolio, making the stock its 15th largest position. Shikiar Asset Management Inc.'s holdings in Incyte were worth $8,138,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Shikiar Asset Management Inc. 在最近向證券交易委員會的披露中表示，在第三季度減少了對 Incyte Corporation (NASDAQ:INCY - 免費報告) 的持股，降幅為 15.8%。該機構投資者在本季度出售了 18,045 股後，持有 95,950 股這家生物製藥公司的股票。Incyte 在 Shikiar Asset Management Inc. 的投資組合中佔約 2.0%，是其第 15 大持倉。Shikiar Asset Management Inc. 在 Incyte 的持股在最近一個季度末價值為 8,138,000 美元。</p>
</div><ul>
<li>Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?</li>
</ul>
<div class="lb-trans"><ul>
<li>Incyte 能否實現 447% 的每股收益預測和管道熱度？</li>
</ul>
</div><p>Other institutional investors have also bought and sold shares of the company. Czech National Bank lifted its stake in shares of Incyte by 6.4% during the 2nd quarter. Czech National Bank now owns 39,271 shares of the biopharmaceutical company's stock worth $2,674,000 after acquiring an additional 2,378 shares during the last quarter. denkapparat Operations GmbH grew its position in Incyte by 46.1% in the 2nd quarter. denkapparat Operations GmbH now owns 11,292 shares of the biopharmaceutical company's stock valued at $769,000 after acquiring an additional 3,564 shares during the last quarter. Hussman Strategic Advisors Inc. increased its stake in Incyte by 20.0% in the second quarter. Hussman Strategic Advisors Inc. now owns 63,000 shares of the biopharmaceutical company's stock worth $4,290,000 after purchasing an additional 10,500 shares during the period. Fisher Asset Management LLC increased its stake in Incyte by 74.6% in the second quarter. Fisher Asset Management LLC now owns 29,922 shares of the biopharmaceutical company's stock worth $2,038,000 after purchasing an additional 12,785 shares during the period. Finally, Strid Group LLC bought a new stake in shares of Incyte during the second quarter worth $999,000. Institutional investors own 96.97% of the company's stock.</p>
<div class="lb-trans"><p>其他機構投資者也買賣了該公司的股票。捷克國家銀行在第二季度將其在 Incyte 的持股增加了 6.4%。捷克國家銀行目前持有 39,271 股這家生物製藥公司的股票，價值 2,674,000 美元，此前在上個季度增持了 2,378 股。denkapparat Operations GmbH 在第二季度將其在 Incyte 的持倉增加了 46.1%。denkapparat Operations GmbH 目前持有 11,292 股這家生物製藥公司的股票，價值 769,000 美元，此前增持了 3,564 股。Hussman Strategic Advisors Inc. 在第二季度將其在 Incyte 的持股增加了 20.0%。Hussman Strategic Advisors Inc. 目前持有 63,000 股這家生物製藥公司的股票，價值 4,290,000 美元，此前增持了 10,500 股。Fisher Asset Management LLC 在第二季度將其在 Incyte 的持股增加了 74.6%。Fisher Asset Management LLC 目前持有 29,922 股這家生物製藥公司的股票，價值 2,038,000 美元，此前增持了 12,785 股。最後，Strid Group LLC 在第二季度購買了價值 999,000 美元的 Incyte 新股。機構投資者目前持有該公司 96.97% 的股票。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other Incyte news, EVP Steven H. Stein sold 20,105 shares of the stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $102.51, for a total transaction of $2,060,963.55. Following the completion of the sale, the executive vice president directly owned 63,129 shares of the company's stock, valued at approximately $6,471,353.79. This represents a 24.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Thomas Tray sold 2,774 shares of the firm's stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $100.00, for a total transaction of $277,400.00. Following the completion of the sale, the insider owned 22,973 shares in the company, valued at $2,297,300. This represents a 10.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 88,318 shares of company stock valued at $8,708,893 in the last three months. 17.80% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 Incyte 的新聞中，執行副總裁 Steven H. Stein 於 12 月 2 日星期二出售了 20,105 股該股票。股票以平均價格 102.51 美元出售，總交易額為 2,060,963.55 美元。出售完成後，該執行副總裁直接持有 63,129 股公司股票，價值約 6,471,353.79 美元。這代表其持股減少了 24.15%。該交易在向 SEC 的文件中披露，可以通過此鏈接訪問。此外，內部人士 Thomas Tray 於 12 月 19 日星期五出售了 2,774 股公司的股票。股票以平均價格 100.00 美元出售，總交易額為 277,400.00 美元。出售完成後，該內部人士在公司中持有 22,973 股，價值 2,297,300 美元。這代表其持股減少了 10.77%。該銷售的披露在 SEC 文件中可用。內部人士在過去三個月內共出售了價值 8,708,893 美元的 88,318 股公司股票。當前 17.80% 的股票由內部人士持有。</p>
</div><h2>Key Incyte News</h2>
<div class="lb-trans"><h2>Incyte 關鍵新聞</h2>
</div><ul>
<li>5 top healthcare stocks for earnings growth in 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年盈利增長的 5 大醫療保健股票</li>
</ul>
</div><p>Here are the key news stories impacting Incyte this week:</p>
<div class="lb-trans"><p>以下是本週影響 Incyte 的關鍵新聞：</p>
</div><ul>
<li>Positive Sentiment: Japan approvals broaden commercial footprint — Japan's health authorities approved Zynyz® (retifanlimab) for first‑line advanced anal cancer and approved Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, opening incremental revenue opportunities in a major market. Read More. Read More.</li>
<li>Positive Sentiment: Analyst momentum and price‑target lifts — Several firms have recently raised targets or upgraded INCY (examples cited include Guggenheim and Barclays), which supports a constructive medium‑term revenue/earnings narrative. Read More.</li>
<li>Neutral Sentiment: Price action shows investor interest but cautions remain — A Zacks write‑up noted a ~5.5% prior session surge on above‑average volume but warned that recent earnings‑estimate revisions may limit near‑term upside, implying momentum may not be durable without further data. Read More.</li>
<li>Negative Sentiment: Insider selling could add selling pressure — Director/officer Thomas Tray disclosed sales totalling 3,374 shares across Dec. 18–19 (avg. ~$98–$100) and other insider transactions were reported; concentrated insider sales can signal near‑term pressure or prompt investor caution. Read More.</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：日本批准擴大商業足跡——日本衞生當局批准了 Zynyz® (retifanlimab) 用於一線晚期肛門癌，並批准了 Minjuvi® (tafasitamab) 與利妥昔單抗和來那度胺聯合用於復發/難治性濾泡淋巴瘤，為一個重要市場開闢了增量收入機會。閲讀更多。閲讀更多。</li>
<li>積極情緒：分析師動能和目標價格上調——幾家公司最近提高了 INCY 的目標或進行了升級（例如 Guggenheim 和 Barclays），這支持了中期收入/盈利的積極敍述。閲讀更多。</li>
<li>中性情緒：價格走勢顯示投資者興趣但仍存謹慎——Zacks 的一篇文章指出，前一交易日的交易量超過平均水平，股價上漲約 5.5%，但警告稱最近的盈利預測修訂可能限制短期上漲，暗示在沒有進一步數據的情況下，動能可能不持久。閲讀更多。</li>
<li>消極情緒：內部人士出售可能增加賣壓——董事/高管 Thomas Tray 披露在 12 月 18 日至 19 日期間共出售 3,374 股（平均價格約為 98–100 美元），並報告了其他內部人士交易；集中內部人士出售可能會發出短期壓力信號或促使投資者保持謹慎。</li>
</ul>
</div><h2>Incyte Stock Down 1.9%</h2>
<div class="lb-trans"><h2>Incyte 股票下跌 1.9%</h2>
</div><p>Shares of NASDAQ INCY opened at $100.71 on Tuesday. The company has a current ratio of 3.20, a quick ratio of 3.13 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $19.77 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 0.70 and a beta of 0.81. The stock's fifty day simple moving average is $98.53 and its two-hundred day simple moving average is $85.09. Incyte Corporation has a 12-month low of $53.56 and a 12-month high of $109.28.</p>
<div class="lb-trans"><p>NASDAQ INCY 的股票在星期二開盤價為 100.71 美元。該公司的流動比率為 3.20，速動比率為 3.13，債務與股本比率為 0.01。該股票的市值為 197.7 億美元，市盈率為 16.87，市盈增長比率為 0.70，貝塔值為 0.81。該股票的 50 日簡單移動平均線為 98.53 美元，200 日簡單移動平均線為 85.09 美元。Incyte Corporation 的 12 個月低點為 53.56 美元，12 個月高點為 109.28 美元。</p>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 激增及有前景的產品提升投資者信心</li>
</ul>
</div><p>Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 EPS for the quarter, topping the consensus estimate of $1.65 by $0.61. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same period in the previous year, the company posted $1.07 EPS. The business's revenue for the quarter was up 20.0% compared to the same quarter last year. As a group, analysts expect that Incyte Corporation will post 4.86 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Incyte (NASDAQ:INCY - 獲取免費報告) 最近於 10 月 28 日星期二發佈了季度財報。這家生物製藥公司報告本季度每股收益為 2.26 美元，超出市場共識預期的 1.65 美元，超出幅度為 0.61 美元。Incyte 的股本回報率為 26.56%，淨利潤率為 24.69%。該公司本季度的收入為 13.7 億美元，而分析師預期為 12.6 億美元。在去年同期，該公司每股收益為 1.07 美元。該公司的季度收入較去年同期增長了 20.0%。整體而言，分析師預計 Incyte Corporation 本財年將發佈 4.86 美元的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價格</h2>
</div><p>Several research analysts recently commented on INCY shares. Stifel Nicolaus raised their price target on shares of Incyte from $110.00 to $115.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, September 22nd. Weiss Ratings reaffirmed a &#34;hold (c+)&#34; rating on shares of Incyte in a research note on Wednesday, October 8th. Morgan Stanley boosted their price target on Incyte from $86.00 to $92.00 and gave the company an &#34;equal weight&#34; rating in a report on Monday, December 8th. Piper Sandler upped their target price on Incyte from $82.00 to $102.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, November 4th. Finally, Barclays increased their price target on Incyte from $101.00 to $115.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, November 24th. Eight investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Hold&#34; and a consensus target price of $99.07.</p>
<div class="lb-trans"><p>幾位研究分析師最近對 INCY 股票發表了評論。Stifel Nicolaus 將 Incyte 的股票目標價從 110.00 美元上調至 115.00 美元，並在 9 月 22 日的研究報告中給予該股票 “買入” 評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Incyte 股票的 “持有（c+）” 評級。摩根士丹利將 Incyte 的目標價從 86.00 美元上調至 92.00 美元，並在 12 月 8 日的報告中給予該公司 “等權重” 評級。Piper Sandler 將 Incyte 的目標價從 82.00 美元上調至 102.00 美元，並在 11 月 4 日的報告中給予該股票 “超配” 評級。最後，巴克萊將 Incyte 的目標價從 101.00 美元上調至 115.00 美元，並在 11 月 24 日的研究報告中給予該股票 “超配” 評級。八位投資分析師對該股票給予了 “買入” 評級，十一位給予了 “持有” 評級，一位則給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “持有”，共識目標價為 99.07 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Incyte</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Incyte 的最新股票分析</strong></p>
</div><h2>About Incyte</h2>
<div class="lb-trans"><h2>關於 Incyte</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.</p>
<div class="lb-trans"><p>Incyte Corporation 是一家總部位於特拉華州威爾明頓的生物製藥公司，專注於腫瘤學和炎症領域新療法的發現、開發和商業化。自 2002 年成立以來，Incyte 已從一家小型研究機構發展為一家全球企業，推進一系列內部開發和合作的資產。公司的研發工作集中在小分子藥物和生物製劑上，這些藥物和生物製劑能夠調節與癌症、自身免疫疾病和罕見疾病相關的關鍵信號通路。</p>
</div><p>The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.</p>
<div class="lb-trans"><p>公司的旗艦產品是 Jakafi®（ruxolitinib），這是一種被批准用於治療骨髓纖維化和真性紅細胞增多症的 Janus 激酶（JAK）抑制劑。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Incyte</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>The Last Gold Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “3 美元人工智能奇蹟股票” 即將爆發</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>資本利得税是否可以扣除任何費用？</li>
<li>最後的黃金牛市</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=INCY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Incyte Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Incyte 嗎？</h2>
</div><p>Before you consider Incyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Incyte 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Incyte 並不在名單上。</p>
</div><p>While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Incyte 目前在分析師中獲得了 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Shikiar 資產管理公司減少了其在因塞特醫療公司$INCY 的股票持倉